Pharmacokinetics, Mass Balance, Safety, and Tolerability of Obeldesivir in Healthy Participants
Open Access
- 28 June 2024
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 116 (5) , 1231-1239
Abstract
There is an unmet need for safe and efficacious oral therapies for COVID‐19 with low potential for drug–drug interactions. Obeldesivir is an orally administered nucleoside prodrug that has shown antiviral potency in nonclinical studies against SARS‐CoV‐2 and its circulating variants. Obeldesivir is metabolized to the active nucleoside triphosphate (GS‐443902), which acts as an inhibitor of the SARS‐CoV‐2 RNA‐dependent RNA polymerase, thereby inhibiting viral RNA synthesis. Here, we report the safety, tolerability, and pharmacokinetics from a first‐in‐human, randomized, placebo‐controlled, phase I study following oral administration of obeldesivir and a phase I, open‐label absorption, distribution, metabolism, and excretion study following oral administration of [14C]‐obeldesivir. Overall, obeldesivir was safe and well tolerated at single and multiple doses between 100 and 1,600 mg, with low potential for QT prolongation as assessed by QT‐concentration analysis. The exposures to GS‐441524 increased dose proportionally in the 100–900‐mg dose range. GS‐441524 accumulated by 35% after twice‐daily and 12% after once‐daily dosing for 5 days. Dose‐proportional increases in the intracellular concentration of GS‐443902 were also observed in peripheral blood mononuclar cells. Plasma exposure of GS‐441524 was not significantly altered by food intake. Following oral administration of [14C]‐obeldesivir (500 mg; 100 μCi), the mean cumulative [14C]‐dose recovery was 90.7% with 58.5% in urine and 32.2% in feces. GS‐441524 was the predominant plasma component (90% of 14C‐area under the concentration–time curve) and was primarily eliminated via renal excretion. Collectively, data from these studies support selection of the obeldesivir 350 mg twice‐daily dosing regimen for further evaluation in phase III studies for COVID‐19.Keywords
Funding Information
- Gilead Sciences
This publication has 10 references indexed in Scilit:
- 539. Efficacy in Multiple SARS-CoV-2 Animal Models Supports Phase 3 Dose Selection for ObeldesivirOpen Forum Infectious Diseases, 2023
- Oral VV116 versus placebo in patients with mild-to-moderate COVID-19 in China: a multicentre, double-blind, phase 3, randomised controlled studyThe Lancet Infectious Diseases, 2023
- Discovery of GS-5245 (Obeldesivir), an Oral Prodrug of Nucleoside GS-441524 That Exhibits Antiviral Efficacy in SARS-CoV-2-Infected African Green MonkeysJournal of Medicinal Chemistry, 2023
- Efficient incorporation and template-dependent polymerase inhibition are major determinants for the broad-spectrum antiviral activity of remdesivirJournal of Biological Chemistry, 2021
- Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication InhibitorClinical Pharmacokinetics, 2021
- Template-dependent inhibition of coronavirus RNA-dependent RNA polymerase by remdesivir reveals a second mechanism of actionJournal of Biological Chemistry, 2020
- Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potencyJournal of Biological Chemistry, 2020
- The Role of Intestinal Carboxylesterase in the Oral Absorption of ProdrugsCurrent Drug Metabolism, 2010
- Evaluation of Methods for Estimating Time to Steady State with Examples from Phase 1 StudiesThe AAPS Journal, 2008
- Plasma-Pooling Methods To Increase Throughput for in Vivo Pharmacokinetic ScreeningJournal of Pharmaceutical Sciences, 1998